Health Advisory:

Updated Clinical Guidance for Health Care Providers

For the 2009-2010 Influenza Season

Please distribute to staff in the Departments of Critical Care, Emergency Medicine, Family Practice, Infection Control, Infectious Disease, Internal Medicine, Laboratory Medicine, Pediatrics, Pulmonary Medicine, and inpatient and outpatient units.

This advisory is intended for providers seeing patients outside of New York City. For guidance related to providers seeing patients in New York City, see the New York City Department of Health and Mental Hygiene (NYCDOHMH) Advisories at: www.nyc.gov/health/nycmed.

This advisory was first released on September 18, 2009. The advisory has been revised to reflect updated recommendations from the Centers for Disease Control and Prevention (CDC) on antiviral medications, and recommendations for the clinical use of influenza diagnostic tests. Information that has been updated or revised is highlighted. In addition, the term “novel H1N1 influenza” has been changed in the advisory to “2009 H1N1 influenza.”

The New York State Department of Health (NYSDOH) is providing the following clinical guidance regarding the upcoming influenza season and the ongoing pandemic of 2009 H1N1 influenza (formerly referred to as novel H1N1 influenza). This advisory updates earlier clinical guidance issued in response to the spring 2009 H1N1 influenza outbreak. The guidance in this advisory is based on currently available information from the CDC, Infectious Diseases Society of America, American Academy of Pediatrics and other sources, and will likely change as additional information becomes available. The focus of this advisory is clinical guidance for health care providers; please see the NYSDOH website at http://www.nyhealth.gov for more detailed information on issues such as influenza surveillance and reporting, vaccination, infection control, and community control measures.

The key points in this advisory include:

- Providers should review regional and state influenza virus surveillance data weekly during the influenza season to determine which types (influenza A or B) and subtypes of influenza A virus (2009 H1N1, seasonal H1N1, or seasonal H3N2) are currently circulating in the area. This information will help guide clinical management decisions, including the appropriate choice of antiviral medication(s) for empiric therapy. Current information on influenza surveillance data in New York State is available on the NYSDOH web site at: http://www.health.state.ny.us/diseases/communicable/influenza/h1n1/health_care_providers/
Providers should initiate early empiric antiviral treatment for hospitalized patients with suspected or confirmed influenza. In addition, providers should consider early empiric treatment for outpatients with suspected or confirmed influenza who are at high risk for complications from influenza.

Persons who are not at higher risk for complications or do not have severe symptoms generally do not require antiviral medications for treatment or prophylaxis.

Rapid influenza diagnostic tests (RIDTs) and direct immunofluorescence assays (DFAs) have low to moderate sensitivity for both seasonal and 2009 H1N1 influenza compared to viral culture or real-time reverse transcription polymerase chain reaction (rRT-PCR) testing. Thus, a negative RIDT or DFA result does not rule out influenza virus infection. If clinical suspicion of influenza is high in a patient who tests negative by RIDT or DFA (or if testing is not offered), empiric antiviral therapy should be administered, if appropriate.

Health care providers should advise people with mild influenza symptoms not to go to the emergency department. Office visits may not be necessary for patients with mild illness. These patients or their parents can be screened by phone, prescribed antiviral medications (if indicated), given symptomatic treatment recommendations, and instructed to contact their health care provider if more serious symptoms develop.

Post-exposure chemoprophylaxis can be considered for persons who are at high risk for influenza complications and who had close contact with a person with influenza. As an alternative to chemoprophylaxis, health care providers may choose to counsel exposed people at higher risk of influenza complications about the signs and symptoms of influenza and advise them to immediately contact their health care provider if signs or symptoms develop.

All medical facilities and offices should strictly adhere to infection control recommendations for influenza.

Patients, especially those who are at high risk for influenza complications, should be vaccinated with seasonal influenza vaccine as soon as possible.

Patients should be vaccinated with H1N1 vaccine according to the priority groups and recommendations established by the CDC’s Advisory Committee on Immunization Practices (ACIP).

Patients who have existing indications for pneumococcal vaccination should be vaccinated according to current ACIP recommendations.

The major changes from previous advisories on 2009 H1N1 influenza include:

- An increased emphasis on the need for providers to be aware of regional and state influenza surveillance data which will impact clinical management decisions.
- Revised physician reporting criteria that focus on patient deaths suspected to be related to influenza. (See Section 4 for the specific reporting criteria.)
- The availability of commercial laboratory testing for 2009 H1N1 influenza. Thus, the NYSDOH Wadsworth Center will no longer offer clinical diagnostic testing for 2009 H1N1 influenza for individual hospitalized patients.

Previous CDC guidance defined children younger than 5 years old as a group at increased risk for influenza-related complications. CDC guidance has been updated with increased emphasis that children younger than 2 years old are at increased risk for influenza-related complications. Children who are 2 years though 4 years of age also have a higher rate of complications compared to older children; although the risk for these children is lower than the risk for children younger than 2 years.

Women up to 2 weeks postpartum (including pregnancy loss) have been added to the groups who are at higher risk for complications from influenza.

Additional guidance for health care providers about promoting early treatment of influenza, including possible strategies to reduce the amount of time between illness onset in high-risk patients and treatment (e.g., educating high-risk patients about the importance of early treatment; ensuring rapid access to telephone consultation and clinical evaluation).
• An alternative to chemoprophylaxis has been added. Health care providers may choose to counsel exposed people at higher risk of influenza complications about the signs and symptoms of influenza and advise them to immediately contact their health care provider if signs or symptoms develop.

• Inclusion of information on the antiviral drug sensitivities of influenza strains expected to circulate during the 2009-2010 influenza season, and recommendations for the selection of antiviral treatment and prophylaxis using influenza surveillance data.

• Change in the recommendation for how long a person with ILI should remain at home. Ill persons should remain home until at least 24 hours after they are free of fever (100°F [37.8°C]), or signs of a fever without the use of fever-reducing medications. (This is a change from the previous recommendation that ill persons stay home for 7 days after illness onset or until 24 hours after the resolution of symptoms, whichever was longer.)

• Section 11, Infection Control Recommendations, was deleted. Infection control guidance will be issued separately.

• Appendix 4, Testing, Treatment and Prophylaxis Decision Algorithm, has been removed. A link to two triage algorithms on the CDC website has been added. A link to a triage algorithm by the American College of Obstetricians and Gynecologists (ACOG) for pregnant women has been added.

### Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Background</td>
<td>3</td>
</tr>
<tr>
<td>2.</td>
<td>Persons at High Risk for Complications from Influenza</td>
<td>4</td>
</tr>
<tr>
<td>3.</td>
<td>Clinical Assessment</td>
<td>4</td>
</tr>
<tr>
<td>4.</td>
<td>Reporting Criteria</td>
<td>5</td>
</tr>
<tr>
<td>5.</td>
<td>Types of Influenza Diagnostic Tests</td>
<td>6</td>
</tr>
<tr>
<td>6.</td>
<td>Influenza Diagnostic Testing in Patients with Suspected Influenza</td>
<td>7</td>
</tr>
<tr>
<td>7.</td>
<td>Patients with Mild Illness</td>
<td>7</td>
</tr>
<tr>
<td>8.</td>
<td>Antiviral Treatment for Influenza</td>
<td>8</td>
</tr>
<tr>
<td>9.</td>
<td>Antiviral Chemoprophylaxis for Influenza</td>
<td>10</td>
</tr>
<tr>
<td>10.</td>
<td>Other Treatment and Prophylaxis Issues</td>
<td>11</td>
</tr>
<tr>
<td>11.</td>
<td>Influenza and Pneumococcal Vaccination</td>
<td>12</td>
</tr>
<tr>
<td>12.</td>
<td>Additional Information</td>
<td>13</td>
</tr>
<tr>
<td>Appx 1</td>
<td>Influenza Antiviral Medication Dosing Recommendations</td>
<td>14</td>
</tr>
<tr>
<td>Appx 2</td>
<td>Antiviral Drug Sensitivities of Influenza Strains Expected to Circulate During the 2009-2010 Influenza Season</td>
<td>16</td>
</tr>
<tr>
<td>Appx 3</td>
<td>Interim Recommendations for the Selection of Antiviral Medications Using Viral Surveillance Data</td>
<td>17</td>
</tr>
</tbody>
</table>

### 1. Background

In April 2009, human cases of 2009 H1N1 influenza infection were first identified. This influenza A virus had not been seen in people before and human-to-human transmission continued throughout the summer months. In June 2009, the World Health Organization (WHO) raised the worldwide pandemic alert level to Phase 6 which indicated that a global pandemic was underway. It is not known at this time how severe the 2009 H1N1 influenza pandemic will be in terms of how many people infected will develop serious complications from infection. However, because 2009 H1N1 influenza is a new virus, many people may have little or no immunity against it, and illness may be more severe and/or widespread.

The CDC and NYSDOH have discontinued reporting of individual case counts. National and state surveillance efforts for 2009 H1N1 influenza are currently focused on severely ill patients and fatalities.
2. Persons at High Risk for Complications from Influenza

It is not known at this time how severe 2009 H1N1 influenza will be in the general population as the pandemic evolves. Severe disease and death caused by 2009 H1N1 influenza infection thus far have affected younger adults, children, pregnant women, and persons of all ages with certain underlying medical conditions more than the elderly.

Current evidence suggests that population immunity to this virus is low, particularly among the young. Widespread susceptibility to this virus among young persons creates the potential for large numbers of cases with more hospitalizations and deaths among younger age groups than would be expected for a typical routine seasonal influenza virus.

Until further information is available, the same groups at increased risk of seasonal influenza-related complications are considered to be at increased risk for 2009 H1N1 influenza-related complications and include the following:

- **Children <5 years**, but especially children younger than 2 years old (see Section 8).
- **Persons with the following underlying medical conditions:**
  - Chronic pulmonary disease, including asthma;
  - Chronic cardiovascular (except isolated hypertension), renal, or hepatic disease;
  - Hematological disorders, including sickle cell disease;
  - Metabolic disorders, including diabetes;
  - Neurologic or neuromuscular disorders that increase the risk for aspiration or compromise the handling of respiratory secretions (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders); or
  - Immunocompromising conditions, including HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure, nephrotic syndrome; those receiving immunosuppressive chemotherapy (including corticosteroids); those who have received an organ or bone marrow transplant; and those who have central nervous system fluid leaks.
- **Persons <19 years** who are receiving long-term aspirin therapy for diseases such as rheumatoid arthritis or Kawasaki disease.
- **Pregnant women** and women up to 2 weeks postpartum (including following pregnancy loss).
- **Residents of nursing homes and other chronic-care facilities.**
- **Adults ≥65 years.** (Note: while elderly persons have had overall lower rates of illness with 2009 H1N1 influenza virus than normally seen during seasonal influenza epidemics, their risk of hospitalizations and death if they become infected is elevated.)

Preliminary studies suggest that people who are morbidly obese (body mass index equal to or greater than 40) and perhaps people who are obese (body mass index 30 to 39) may be at increased risk of hospitalization and death due to 2009 H1N1 influenza infection. Additional studies to determine the risk of obesity for these complications of 2009 H1N1 influenza virus infection are underway.

3. Clinical Assessment

It is not possible to distinguish between seasonal influenza infection, 2009 H1N1 influenza infection, and infections with other respiratory viruses based solely on a patient’s clinical presentation. Depending on the clinical test used, influenza testing may not be sensitive or timely enough to assist with initial patient management decisions. There is also the added challenge of differing antiviral resistance patterns of influenza strains, which impacts the choice of antiviral treatment. Thus, providers will need to consider several factors when making initial patient management decisions, including:

- current levels of both seasonal influenza and 2009 H1N1 influenza activity in the community;
- results of any rapid influenza diagnostic testing, if performed;
• severity of the patient’s illness; and
• presence of any underlying medical conditions that places the patient at higher risk for complications from influenza.

Clinical Presentation
Clinicians should consider 2009 H1N1 influenza or seasonal influenza infection in the differential diagnosis of any person presenting with an unexplained acute febrile respiratory illness, including:
• ILI (defined as a measured temperature $\geq 37.8^\circ C \text{[100°F]}$ with cough or sore throat);
• pneumonia and fever;
• acute respiratory distress syndrome (ARDS) and fever; or
• respiratory distress and fever.

Patients with 2009 H1N1 influenza infection are likely to present with symptoms similar to typical, seasonal ILI. In addition to fever, cough, and sore throat, patients with confirmed uncomplicated 2009 H1N1 influenza infection have reported chills, headache, rhinorrhea, shortness of breath, myalgias, fatigue, nausea, abdominal pain, and diarrhea. Providers should keep in mind that, as with seasonal influenza, infants, elderly adults, and persons with compromised immune systems may have atypical presentations, such as presenting without a fever, sepsis-like syndrome, or an unexplained exacerbation of a chronic lung or heart condition.

Algorithms for the triage of adults (>18 years) and children (<18 years) with ILI are available on the CDC website at: [http://www.cdc.gov/h1n1flu/guidance/](http://www.cdc.gov/h1n1flu/guidance/) An algorithm for the assessment and treatment of pregnant women with ILI is available on the American College of Obstetricians and Gynecologists (ACOG) website at: [http://www.acog.org/departments/resourceCenter/2009H1N1TriageTreatment.pdf](http://www.acog.org/departments/resourceCenter/2009H1N1TriageTreatment.pdf)

4. Reporting Criteria

Community Case Reporting
Physician reporting will be focused on patient deaths suspected to be related to influenza. All physicians should report immediately by telephone to the local health department (LHD) any patient deaths meeting the following reporting criteria:
• Deaths among adult and pediatric patients involving an unexplained acute respiratory febrile illness.
• Deaths among adult and pediatric patients suspected or confirmed to have 2009 H1N1 influenza.
• Deaths among pediatric patients suspected or confirmed to be related to any type of influenza (2009 H1N1 influenza or seasonal influenza).

For all pediatric deaths, the LHD will coordinate with the coroner or medical examiner to facilitate appropriate follow-up, including an autopsy examination and submission of specimens for testing at the NYSDOH Wadsworth Center and/or CDC. The LHD may also request clinical information about the deceased patient for completion of a case report for submission to the NYSDOH. While autopsies may be requested, consent is generally required.

For adult deaths, there is no longer a need to conduct routine autopsies for influenza surveillance. The LHD may request clinical information about the deceased patient for completion of a case report for submission to the NYSDOH. Autopsy can be considered if the case presented with unusual disease processes (based on clinical judgment) prior to death. If an autopsy is done and reveals unusual pathologic findings, submission of specimens for further testing at the NYSDOH Wadsworth Center will be considered on a case-by-case basis.

Providers should also continue to report patients with milder ILI who are part of a community outbreak (especially patients who are from congregate facilities such as group homes and day care settings). A
community outbreak is generally defined as a cluster of illness above baseline among epidemiologically linked cases. The LHD will determine if an investigation or further follow-up is indicated. If there are difficulties reaching the LHD, the provider should contact the NYSDOH. During business hours, call 518-473-4439; after hours, call 1-866-881-2809.

**Health care Facility Outbreak Reporting**

In addition to the reporting criteria above, NYSDOH-regulated health care facilities must report to the NYSDOH any instance of nosocomial transmission of influenza, including:

- A single nosocomial case of confirmed influenza in a facility patient/resident or staff member
- Clusters of ILI among health care workers and patients/residents of a facility (defined as two or more cases on the same unit within 7 days)

Reports should be submitted via the Nosocomial Outbreak Reporting Application (NORA) system located on the Health Provider Network (HPN) at [https://commerce.health.state.ny.us/hpn/infecontrol/forms.html](https://commerce.health.state.ny.us/hpn/infecontrol/forms.html). The appropriate NYSDOH Regional Epidemiology office or NYCDOHMH office will follow up with the facility making the report.

For questions regarding nosocomial reporting, please contact the appropriate NYSDOH Regional Epidemiology office as listed on the following website: [http://www.health.state.ny.us/professionals/diseases/reporting/communicable/infection/regional_epi_staff.htm](http://www.health.state.ny.us/professionals/diseases/reporting/communicable/infection/regional_epi_staff.htm) or the NYCDOHMH Influenza Surveillance Coordinator at (212) 442-9050 or (212) 788-4150. To reach the NYSDOH after hours, call 1-866-881-2809.

### 5. Types of Influenza Diagnostic Tests

There are several types of laboratory diagnostic tests that can be used for detecting the presence of influenza viruses in respiratory specimens, including RIDTs, DFAs, viral culture and rRT-PCR. These tests differ in their sensitivity and specificity in detecting influenza viruses, the amount of time needed from specimen collection until results are available, and the tests’ ability to distinguish between different influenza virus types and subtypes.

#### Rapid Influenza Diagnostic Tests (RIDTs)

RIDTs detect influenza viral nucleoprotein antigen. Commercially available RIDTs can either: 1) detect and distinguish between influenza A and B viruses; 2) detect both influenza A and B viruses but not distinguish between influenza A and B viruses; or 3) detect only influenza A viruses. None of the currently FDA-approved RIDTs can distinguish between influenza A subtypes (for example, distinguish between the 2009 H1N1 influenza A virus and seasonal influenza A viruses). Also, RIDTs cannot provide any information about antiviral drug susceptibility.

Because RIDTs can provide results within 30 minutes or less, they may provide some timely information to help guide initial clinical decisions regarding the management of patients with an acute febrile respiratory illness. However, RIDTs have low to moderate sensitivity (range 10-70%) for both seasonal and 2009 H1N1 influenza compared to rRT-PCR. Thus, a negative rapid test result does not rule out influenza virus infection. Since false negative results can occur, if clinical suspicion of influenza is high in a patient who tests negative by RIDT (or if RIDT is not offered), early, empiric antiviral therapy should be administered, if appropriate. (See Section 8 on antiviral treatment for further details.)

#### Direct Immunofluorescence Assays (DFAs)

DFAs are widely available and have variable sensitivity (range 47 – 93%) for 2009 H1N1 influenza virus. DFAs detect and distinguish between influenza A and B viruses but do not distinguish among different influenza A subtypes. A negative DFA test does not rule out influenza virus infection.
**Viral Isolation in Tissue Cell Culture**

Viral isolation in tissue cell culture is more sensitive than RIDT and DFA but its availability is limited and results may take two to 10 days. 2009 H1N1 influenza can be distinguished from other influenza A viruses if additional testing is done on the isolate, but this is available at a limited number of laboratories.

**Nucleic Acid Amplification Tests**

Nucleic acid amplification tests, including rRT-PCR, are the most sensitive and specific influenza diagnostic tests, but obtaining test results may take one to several days. As with any assay, false negatives can occur. Nucleic acid amplification tests are available in NYS through a number of commercial and clinical hospital laboratories.

Few nucleic acid amplification assays can specifically differentiate 2009 H1N1 influenza virus from other influenza A viruses. If specific testing for 2009 H1N1 influenza virus is required, testing with an rRT-PCR assay specific for 2009 H1N1 influenza should be performed. This is now available to NYS patients at several commercial and hospital laboratories.

Public health laboratory testing for 2009 H1N1 influenza will not be routinely available to providers or facilities for primary testing. The NYSDOH Wadsworth Center will no longer offer clinical diagnostic testing for 2009 H1N1 influenza for individual hospitalized patients. Patient specimens for routine diagnostic testing should be submitted to hospital or commercial laboratories that can test for 2009 H1N1 influenza. Public health testing will focus primarily on surveillance, but will be available for special circumstances on a case by case basis, such as where antiviral susceptibility testing may be indicated (e.g., failure to respond to antiviral therapy or development of illness while on prophylactic antiviral therapy). Such cases should be reported to the LHD, where staff will review the case and discuss appropriate testing with the NYSDOH.

6. **Influenza Diagnostic Testing in Patients with Suspected Influenza**

*Patients hospitalized with an acute febrile respiratory illness:* Providers should consider laboratory testing for influenza by commercially available tests (RIDT; DFA; rRT-PCR; or culture). Providers should take into consideration the limitations of the diagnostic test used and antiviral treatment should not wait for laboratory confirmation of influenza.

Since a negative RIDT or DFA test result does not exclude influenza virus infection, hospitalized patients with a negative RIDT or DFA result should have priority for further testing with a nucleic acid amplification test, such as rRT-PCR, if influenza infection is clinically suspected. Testing and treatment for bacterial pathogens and other respiratory viruses should be conducted as appropriate. In addition, patient deaths meeting the reporting criteria outlined in Section 4 should be reported to the LHD for possible further testing.

*High-risk patients with milder influenza illness in the outpatient setting:* Providers may also consider commercially available influenza testing for high-risk patients in the outpatient setting who have milder ILI symptoms if it will provide useful information that impacts the care of these patients. Providers should take into consideration the limitations of the diagnostic test used. Antiviral treatment should not wait for laboratory confirmation of influenza.

*Patients with mild illness and not at high risk for complications from influenza:* For these patients, influenza testing is usually not indicated because testing will not influence treatment decisions.

7. **Patients with Mild Illness**

Health care providers should advise people with mild influenza symptoms not to go to the emergency department. Patients with mild illness may not need to be seen in the office. These patients can be
screened by phone, prescribed antiviral medications (if indicated – e.g., if the patient is at high risk for influenza complications), given symptomatic treatment recommendations, and instructed to contact their health care provider if more serious symptoms develop.

Patients with mild illness should be provided with educational information about preventing influenza transmission and advised to stay home until at least 24 hours after they are free of fever (100°F [37.8°C]), or signs of a fever without the use of fever-reducing medications. Guidance for taking care of a sick person in the home can be found at: http://www.cdc.gov/h1n1flu/guidance_homecare.htm.

8. Antiviral Treatment for Influenza

Antiviral treatment is recommended for:
- Patients hospitalized with confirmed or suspected influenza.
- Patients with suspected or confirmed influenza who are severely ill or who are showing evidence of rapid clinical deterioration. Signs and symptoms of severe illness due to suspected influenza are an indication for immediate treatment, regardless of previous health or age.

Antiviral treatment should be considered for:
- Outpatients who are at higher risk for influenza-related complications (see Section 2 for a list of high-risk conditions). Clinical judgment should be used in deciding whether outpatients with risk factors for influenza-related complications require treatment.

Since no vaccine is 100% effective, a history of receipt of 2009 H1N1 vaccine or seasonal influenza vaccine does not rule out influenza infection. Early empiric treatment should be initiated for persons with suspected influenza, when indicated, regardless of the individual’s influenza vaccination status.

Clinical judgment is an important factor in treatment decisions. Persons with suspected influenza infection who present with an uncomplicated febrile illness typically do not require treatment unless they are at higher risk for influenza complications. For most patients without any underlying medical conditions, the benefits of using antiviral medications may be modest. However, any suspected influenza patient who presents with emergency warning signs (e.g., difficulty breathing or shortness of breath) or signs of lower respiratory tract illness should promptly receive antiviral therapy.

Antiviral treatment should be initiated as soon as possible (ideally within 48 hours) after the onset of symptoms. For patients with severe disease and/or who are at high risk for complications, treatment can be initiated at any point, but is most effective earlier in the course of illness. Recommended duration of treatment is 5 days. Hospitalized patients with severe infection may require longer treatment courses.

Obese Patients

Obese patients often have underlying conditions that put them at increased risk for complications due to 2009 H1N1 influenza infection, such as diabetes, asthma, chronic respiratory illness, or liver disease. Patients with confirmed or suspected influenza and who are obese should be carefully evaluated for the presence of underlying medical conditions that are known to increase the risk for influenza complications, and receive empiric treatment when these conditions are present.

Infants and Young Children

The risk of influenza-associated hospitalizations in healthy children younger than 2 years old is equal to or greater than the risk of other high-risk groups. Given this increased risk for hospitalization, children younger than 2 years old are generally recommended for antiviral treatment.
Children 2 to 4 years old are more likely to require hospitalization or urgent medical evaluation for influenza compared with older children, although the risk is much lower than for children younger than 2 years old. Children aged 2 years to 4 years without high risk conditions (see Section 2) and with mild illness do not necessarily require antiviral treatment. Health care providers should use clinical judgment to guide treatment decisions.

**Strategies to Promote Early Treatment**

Providers should implement strategies to promote the early treatment of influenza among their high-risk patients. Strategies include: educating patients at higher risk for influenza complications about the signs and symptoms of influenza and the need for early treatment after symptom onset; ensuring rapid access to telephone consultation and clinical evaluation for these patients as well as patients who report severe illness; and considering empiric treatment of patients at higher risk for influenza complications based on telephone contact. Algorithms for the triage of adults (>18 years) and children (< 18 years) with ILI are available on the CDC website at: [http://www.cdc.gov/h1n1flu/guidance/](http://www.cdc.gov/h1n1flu/guidance/). An algorithm for the assessment and treatment of pregnant women with ILI is available on the American College of Obstetricians and Gynecologists (ACOG) website at: [http://www.acog.org/departments/resourceCenter/2009H1N1TriageTreatment.pdf](http://www.acog.org/departments/resourceCenter/2009H1N1TriageTreatment.pdf)

Patients should be educated about their continued susceptibility to influenza virus infection after treatment is completed (because of other circulating influenza viruses or if illness was due to another cause), and the need to again seek early access to health care consultation if symptoms recur.

**Choice of Antiviral Medication for Treatment**

Health care providers will need to make decisions about which antiviral medication to use for treatment by taking into consideration the influenza activity in New York State and the antiviral susceptibility patterns of the circulating strains. Evidence from other states and the southern hemisphere suggests that 2009 H1N1 influenza virus will remain the dominant influenza strain this season. However, health care providers should review weekly their regional and state influenza virus surveillance data to determine which types (influenza A or B) and subtypes of influenza A virus (2009 H1N1 influenza, seasonal H1N1 influenza, or seasonal H3N2 influenza) are currently circulating in the area. Current information on influenza surveillance data in New York State is available at: [http://www.health.state.ny.us/diseases/communicable/influenza/h1n1/health_care_providers/](http://www.health.state.ny.us/diseases/communicable/influenza/h1n1/health_care_providers/)

The following recommendations are based on antiviral susceptibility patterns current as of October 2009. (See Appendix 2 for antiviral drug sensitivities of influenza strains that may circulate during the 2009-2010 influenza season.)

- Oseltamivir or zanamivir should be used to treat individuals with 2009 influenza A (H1N1), influenza A (H3N2), or influenza B. For the treatment of pregnant women, oseltamivir is preferred due to its systemic activity.
- Zanamivir should be used to treat individuals with seasonal influenza A (H1N1).
  - Rimantadine can be used for patients who cannot receive zanamivir (e.g., patient is <7 years old, has chronic underlying pulmonary disease, or cannot use the zanamivir inhalation device) or if zanamivir is unavailable.
  - Amantadine can be substituted for rimantadine if rimantadine is unavailable.
- Zanamivir or a combination of oseltamivir and rimantadine should be used if:
  - The patient’s subtype information is not available and multiple influenza strains are circulating including seasonal influenza A (H1N1), or
  - Influenza surveillance information is not available or unknown.
  - Use of zanamivir or combination therapy with oseltamivir and rimantadine will provide effective treatment against all possible circulating influenza viruses.
See Appendix 3 for a summary table of recommendations for the selection of antiviral medications based on influenza surveillance data.

Note that zanamivir is not recommended for patients with underlying pulmonary disease, such as asthma or chronic obstructive pulmonary disease. See Appendix 1 for antiviral medication dosing recommendations. Some experts recommend the use of increased (doubled doses) of oseltamivir for some severely ill patients, although there are no published data on its effectiveness. Dosages of some antiviral medications may need to be adjusted for persons age 65 years and older, persons with impaired renal function, or persons with liver disease. Clinicians should consult the package insert of each antiviral medication for additional dosing information, contraindications/warnings/precautions, and adverse effects.

9. **Antiviral Chemoprophylaxis for Influenza**

Post-exposure prophylaxis can be considered for persons who are at high risk for influenza complications and who had close contact with a person with influenza during the ill person’s infectious period (defined as 1 day prior to onset of symptoms until 24 hours after fever ends). (See Section 2 for a list of high-risk conditions.) When chemoprophylaxis is indicated, antiviral medication should be initiated as soon as possible following the exposure and should continue for 10 days following the last known exposure to influenza. Chemoprophylaxis generally is not recommended if more than 48 hours have elapsed since the last contact with an infectious person.

Patients given post-exposure chemoprophylaxis should be informed that the chemoprophylaxis lowers but does not eliminate the risk of influenza and that protection stops when the medication course is stopped. Patients receiving chemoprophylaxis should be encouraged to seek medical evaluation as soon as they develop a febrile respiratory illness that might indicate influenza.

**Alternative to Chemoprophylaxis**

As an alternative to chemoprophylaxis, health care providers may choose to counsel exposed people at higher risk of influenza complications about the signs and symptoms of influenza and advise them to immediately contact their health care provider if signs or symptoms develop. Health care providers should use clinical judgment regarding situations where early recognition of illness and treatment might be an appropriate alternative. Providers may choose to give the exposed patient a prescription for an influenza antiviral and may want to request that the patient contact the provider if signs or symptoms of influenza develop, obtain antiviral medications as quickly as possible, and start treatment.

**Choice of Antiviral Medication for Chemoprophylaxis**

Persons who are candidates for post-exposure chemoprophylaxis should be provided with medications most likely to be effective against the influenza virus that is the cause of the close contact’s illness, if known. Health care providers should also be aware of state influenza activity and antiviral susceptibility patterns of the circulating strains. Evidence from other states and the southern hemisphere suggests that 2009 H1N1 influenza virus will remain the dominant influenza strain this season.

The following recommendations are based on antiviral susceptibility patterns current as of October 2009. (See Appendix 2 for antiviral drug sensitivities of influenza strains that may circulate during the 2009-2010 influenza season.)

- Oseltamivir or zanamivir should be used for exposure to a person with 2009 influenza A (H1N1), influenza A (H3N2) or influenza B.
- Zanamivir should be used for exposure to a person with seasonal influenza A (H1N1).
Rimantadine can be for patients who cannot receive zanamivir (e.g., patient is <7 years old, has chronic underlying airways disease, or cannot use the zanamivir inhalation device) or if zanamivir is unavailable.

Amantadine can be substituted for rimantadine if rimantadine is unavailable.

- Zanamivir or a combination of oseltamivir and rimantadine should be used if:
  - subtype information is not available and multiple influenza strains are circulating, including seasonal influenza A (H1N1), or
  - influenza surveillance information is not available or unknown.
  - Use of zanamivir or combination therapy with oseltamivir and rimantadine will provide effective prophylaxis against all possible circulating influenza viruses.

See Appendix 3 for a summary table of recommendations for the selection of antiviral medications based on influenza surveillance data.

Note that zanamivir is not recommended for patients with underlying pulmonary disease, such as asthma or chronic obstructive pulmonary disease. See Appendix 1 for antiviral medication dosing recommendations; dosages of some antiviral medications may need to be adjusted for persons age 65 years and older, persons with impaired renal function, or persons with liver disease. Clinicians should also consult the package insert of each antiviral medication for additional dosing information, contraindications/warnings/precautions, and adverse effects.

## 10. Other Treatment and Prophylaxis Issues

### Oseltamivir-Resistant 2009 H1N1 Influenza

To date, there have been sporadic reports of persons with oseltamivir-resistant 2009 H1N1 influenza virus infection. These reports have typically occurred among persons who developed illness while receiving oseltamivir for chemoprophylaxis or immunocompromised patients with influenza who were being treated. Since these reports are rare, the CDC’s interim recommendations for the treatment and chemoprophylaxis of 2009 H1N1 influenza have not changed and oseltamivir continues to be an option. Inappropriate use of oseltamivir for chemoprophylaxis could contribute to the increased development of oseltamivir resistance among 2009 H1N1 influenza viruses. Antiviral agents for chemoprophylaxis should be used judiciously; chemoprophylaxis should be reserved for persons at high risk for influenza complications who have been exposed to a person with influenza.

### Antiviral Medications and Live Attenuated Influenza Vaccine

Antiviral medications may interfere with a person’s immune response to the live attenuated influenza vaccine (LAIV). If a person is taking an influenza antiviral medication, LAIV should not be given until 48 hours after the last dose of the influenza antiviral medication. If a person has received LAIV, influenza antiviral medication taken within 2 weeks after receipt of LAIV may interfere with the person’s response to the vaccine. Trivalent inactivated influenza vaccine can be administered at any time relative to use of an antiviral medication.

### Personal Stockpiles of Antiviral Medications

The NYSDOH strongly discourages physicians and other health care providers from prescribing antiviral medications for well patients who are not at high risk for influenza complications to stockpile now for possible future use. Repeated dosing of antivirals in the absence of medical indications is not advised for the following reasons:

- Inappropriate or inconsistent use of antivirals may increase the risk of drug resistance.
- Susceptibility of the prescribed antiviral for a future circulating strain is unknown.
- Use of antivirals without the guidance of a physician may increase the risk of adverse effects or drug interactions.
**Bacterial Co-Infection**

Influenza-related complications for both seasonal and 2009 H1N1 influenza include possible bacterial co-infection and pneumonia. Bacterial etiologic agents have included *Streptococcus pneumoniae*, methicillin-resistant *Staphylococcus aureus* (MRSA), methicillin-sensitive *Staphylococcus aureus* (MSSA), Group A *Streptococcus*, and *Haemophilus influenzae*. Providers should consider the possibility of bacterial co-infection in their patients and evaluate for the potential need for antibiotics.

**Fever in Pregnant Women**

Fever in pregnant women should be promptly treated with acetaminophen because maternal hyperthermia has been associated with various adverse fetal and neonatal outcomes.

**11. Influenza and Pneumococcal Vaccination**

**Seasonal Influenza Vaccination**

Providers are strongly encouraged to vaccinate their patients with seasonal flu vaccine as soon as possible, especially those who are at high risk for influenza complications. The usual seasonal influenza viruses are still expected to cause illness this fall and winter; vaccinating patients with seasonal vaccine is not only an important prevention strategy, it may help reduce the overall burden on the health care system during the influenza season. Seasonal vaccine is available earlier than the H1N1 vaccine, and providers should begin seasonal vaccination efforts as soon as possible. Information on seasonal influenza vaccine can be found at: [http://www.cdc.gov/flu/professionals/acip/index.htm](http://www.cdc.gov/flu/professionals/acip/index.htm)

**H1N1 Influenza Vaccination**

H1N1 vaccine has begun to be distributed in New York State. Health care providers who want to receive the H1N1 vaccine must register with the NYSDOH and electronically sign Provider Agreements required by the CDC. The first batches of vaccine provided by the CDC to states have been small, with larger allocations provided in succeeding weekly shipments. Additional information about H1N1 vaccine, including how to obtain the vaccine, can be found on the NYSDOH web site at: [http://www.health.state.ny.us/diseases/communicable/influenza/h1n1/health_care_providers/](http://www.health.state.ny.us/diseases/communicable/influenza/h1n1/health_care_providers/)

CDC’s ACIP has recommended that five priority groups receive the H1N1 vaccine as it first becomes available this fall. These groups include:

- pregnant women,
- people who live with or care for children younger than 6 months of age,
- health care and emergency medical services personnel,
- persons between the ages of 6 months and 24 years old, and
- people ages of 25 through 64 years of age who are at higher risk for complications from H1N1 because of chronic health disorders or compromised immune systems.

Once the demand for vaccine for all of the prioritized groups above have been met at the local level, programs and providers should begin vaccinating everyone from ages 25 through 64 years. Current studies indicate the risk for infection among persons age 65 years or older is less than the risk for younger age groups. Therefore, once vaccine supply and demand for vaccine among younger age groups has been met, programs and providers should offer vaccination to people over the age of 65 years.

**Pneumococcal Vaccination**

During influenza outbreaks, pneumococcal vaccines may be useful in preventing secondary pneumococcal infections and reducing illness and death. Currently, two vaccines are available for prevention of pneumococcal disease, a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 7-valent pneumococcal conjugate vaccine (PCV7).
CDC’s ACIP recommends a single dose of PPSV23 for all people 65 years and older and for persons 2 to 64 years of age with certain high-risk conditions. A single revaccination at least five years after initial vaccination is recommended for: 1) people 65 years and older who were first vaccinated before age 65 years, and 2) people at highest risk, such as those who have no spleen, and those who have HIV infection, AIDS, or malignancy. Patients who have existing indications for PPSV23 should continue to be vaccinated according to current ACIP recommendations. PPSV23 may be administered on the same day as any of the influenza vaccines. Use of PPSV23 among people without current indications for vaccination is not recommended at this time.

PPSV23 may be administered on the same day as any of the influenza vaccines. Use of PPSV23 among people without current indications for vaccination is not recommended at this time.

PCV7 is recommended for all children up to 59 months of age. Health care providers should continue to vaccinate this population according to current ACIP recommendations. For more information about recommendations for use of pneumococcal vaccines, please see: http://www.cdc.gov/h1n1flu/guidance/PPSV_h1n1.htm.

12. Additional Information
The NYSDOH will provide updated guidance as information and recommendations become available. For additional information on this evolving situation, please refer to the following websites:

- New York State Department of Health: http://www.nyhealth.gov
- New York City Department of Health and Mental Hygiene: www.nyc.gov/health/nycmed
- Centers for Disease Control and Prevention: http://www.cdc.gov/h1n1flu/
- Infectious Diseases Society of America: http://www.idsociety.org/Content.aspx?id=14220
- World Health Organization: http://www.who.int/en/
**Appendix 1**

**Influenza Antiviral Medication Dosing Recommendations**

Table 1: Antiviral medication dosing recommendations for adults and children 12 months of age and older

(Table 1 adapted from Infectious Diseases Society of America guidelines for seasonal influenza)

<table>
<thead>
<tr>
<th>Agent, group</th>
<th>Treatment (5 days)</th>
<th>Chemoprophylaxis (10 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neuraminidase inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oseltamivir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults</td>
<td>75 mg capsule twice per day</td>
<td>75 mg capsule once per day</td>
</tr>
<tr>
<td>Children (age 12 months or older) by weight</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤15 kg</td>
<td>60 mg per day divided into 2 doses</td>
<td>30 mg once per day</td>
</tr>
<tr>
<td>15-23 kg</td>
<td>90 mg per day divided into 2 doses</td>
<td>45 mg once per day</td>
</tr>
<tr>
<td>24-40 kg</td>
<td>120 mg per day divided into 2 doses</td>
<td>60 mg once per day</td>
</tr>
<tr>
<td>&gt;40 kg</td>
<td>150 mg per day divided into 2 doses</td>
<td>75 mg once per day</td>
</tr>
<tr>
<td>Zanamivir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults</td>
<td>Two 5-mg inhalations (10 mg total) twice per day</td>
<td>Two 5-mg inhalations (10 mg total) once per day</td>
</tr>
<tr>
<td>Children</td>
<td>Two 5-mg inhalations (10 mg total) twice per day (age, 7 years or older)</td>
<td>Two 5-mg inhalations (10 mg total) once per day (age, 5 years or older)</td>
</tr>
<tr>
<td>Adamantanes&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rimantadine&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults</td>
<td>200 mg per day, either as a single daily dose or divided into 2 doses</td>
<td>200 mg per day, either as a single daily dose or divided into 2 doses</td>
</tr>
<tr>
<td>Children (age, 1-9 years)</td>
<td>6.6 mg/kg per day (maximum, 150 mg per day) divided into 2 doses</td>
<td>5 mg/kg per day once daily, not to exceed 150 mg</td>
</tr>
<tr>
<td>Children (age, 10 years and older)</td>
<td>200 mg per day, either as a single daily dose or divided into 2 doses</td>
<td>200 mg per day, either as a single daily dose or divided into 2 doses</td>
</tr>
<tr>
<td>Amantadine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults</td>
<td>200 mg per day, either as a single daily dose or divided into 2 doses</td>
<td>200 mg per day, either as a single daily dose or divided into 2 doses</td>
</tr>
<tr>
<td>Children (age, 1-9 years)</td>
<td>5-8 mg/kg per day divided into 2 doses or as a single daily dose (maximum, 150 mg per day)</td>
<td>5-8 mg/kg per day divided into 2 doses or as a single daily dose (maximum, 150 mg per day)</td>
</tr>
<tr>
<td>Children (age, 10-12 years)</td>
<td>200 mg per day divided into 2 doses</td>
<td>200 mg per day divided into 2 doses</td>
</tr>
</tbody>
</table>

<sup>a</sup> Adamantanes should be used only in situations where seasonal H1N1 influenza infection or exposure is suspected.

<sup>b</sup> Rimantadine has not been approved by the US Food and Drug Administration (FDA) for treatment of influenza of children, but published data exist on safety and efficacy in the pediatric population.

Clinicians should consult the package insert of each antiviral medication for specific dosing information, approved indications and ages, contraindications/warnings/precautions, and adverse effects.
**Table 2: Oseltamivir medication dosing recommendations for children less than 12 months of age**

<table>
<thead>
<tr>
<th>Agent, group</th>
<th>Treatment (5 days)</th>
<th>Chemoprophylaxis (10 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oseltamivir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children (age &lt;12 months)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;3 months</td>
<td>12 mg twice daily</td>
<td>Not recommended unless situation judged critical due to limited data on use in this age group</td>
</tr>
<tr>
<td>3-5 months</td>
<td>20 mg twice daily</td>
<td>20 mg once daily</td>
</tr>
<tr>
<td>6-11 months</td>
<td>25 mg twice daily</td>
<td>25 mg once daily</td>
</tr>
</tbody>
</table>

* Oseltamivir use for children < 12 months old was approved in April 2009 by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) in response to the 2009 H1N1 influenza outbreak. Dosing for children <12 months is age-based. Health care providers should be aware of the lack of data on safety and dosing when considering oseltamivir use in young infants, and carefully monitor infants for adverse events when oseltamivir is used.


Note: Some experts prefer weight-based dosing for children aged younger than 1 year, particularly for very young or premature infants.
Antiviral drug sensitivities of influenza strains expected to circulate during the 2009-2010 influenza season

<table>
<thead>
<tr>
<th>Influenza Strain (2009-2010)</th>
<th>Amantadine (Symmetrel)</th>
<th>Oseltamivir (Tamiflu)</th>
<th>Zanamivir (Relenza)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seasonal influenza A (H1N1) virus (A/Brisbane/59/2007)</td>
<td>Susceptible</td>
<td>Resistant</td>
<td>Susceptible</td>
</tr>
<tr>
<td>2009 influenza A (H1N1) virus</td>
<td>Resistant</td>
<td>Susceptible</td>
<td>Susceptible</td>
</tr>
<tr>
<td>Seasonal influenza A (H3N2) virus (A/Brisbane/10/2007)</td>
<td>Resistant</td>
<td>Susceptible</td>
<td>Susceptible</td>
</tr>
<tr>
<td>Seasonal influenza B (B/Brisbane 60/2008, Victoria lineage)</td>
<td>Not effective</td>
<td>Susceptible</td>
<td>Susceptible</td>
</tr>
</tbody>
</table>

Source: American Academy of Pediatrics Committee on Infectious Diseases: Recommendations for Prevention and Control of Influenza in Children, 2009-2010
Appendix 3

Interim recommendations for the selection of antiviral medications using viral surveillance data*

<table>
<thead>
<tr>
<th>Influenza virus(es) in the community</th>
<th>Preferred medication(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009 influenza A (H1N1) and/or Influenza A (H3N2) and/or Influenza B</td>
<td>Oseltamivir or Zanamivir</td>
</tr>
<tr>
<td>Seasonal influenza A (H1N1)</td>
<td>Zanamivir or Rimantadine**</td>
</tr>
<tr>
<td>Multiple influenza types/subtypes, including seasonal H1N1, are circulating or Surveillance data unknown or not available</td>
<td>Zanamivir or Combination oseltamivir and rimantadine**</td>
</tr>
</tbody>
</table>

* If rapid influenza diagnostic testing is performed and is positive for influenza B, infection with influenza B virus is likely. Treatment with either oseltamivir or zanamivir is appropriate, regardless of other circulating strains in the community.

**Amantadine can be substituted for rimantadine but has increased risk of adverse events.

Clinicians should consult the package insert of each antiviral medication for specific dosing information, approved indications and ages, contraindications/warnings/precautions, and adverse effects.